BM was collected from the anterior and posterior iliac crests and occasionally the sternum as previously described.26
Cell counts were done intraoperatively to ensure that a minimum of 2 x 10 cells/kg body weight were harvested. The cells were mixed with heparinized RPMI 1640 media (M. A. Bioproducts, Walkersville, MD) with a final heparin concentration of 6 to 7 U/mL marrow.
No further heparin was added during the processing procedure.
After filtering, the entire marrow volume was placed into a single 2,000-mL plasma transfer bag (Fenwal Labs, Deerfield, IL). The subsequent processing was done as a closedsystem technique.
To minimize nucleated BM cell loss, the red cells were initially sedimented from the BM by using 6% HES (Hespan; American Critical Care) at 1 vol to 8 vol of BM. The RBCs were allowed to settle for 60 minutes at room temperature. The sedimented RBCs and the cell-rich plasma were each transferred to 600-mL transfer bags and then centrifuged for ten minutes at 400 g at 4#{176}C. The buffy coat cells from the sedimented RBC layer were added to those from the cell-rich plasma and the volume of the combination adjusted to 300 mL with RPMI 1640 tissue culture media. One hundred fifty milliliters of both the cells and the cryoprotectant was simultaneously added to two polyolefin freezing bags (4403-2; Delmed, Canton, MA). The bags were sealed, placed into aluminum freezing frames, and placed horizontally into a -80#{176}C freezer where they remained until reinfusion. Cell counts were recorded before and after the initial processing of the BM and after thawing the cells. Trypan blue dye exclusion testing was done postthaw, and committed stem cell assays were done both before and after the cryopreservation procedure, with the postthaw handling of the BM as previously described.2'
The cryopreserved BM was thawed at the patients' bedside in a 37#{176}C water bath. Each 300-mL bag was infused through a central venous catheter, without filtering, for more than 30 minutes. Preparative regimens.
The preparative regimens varied depending primarily on the tumor being treated. In 30 cases high-dose carmustine (BCNU; 900 mg/rn2) was used, usually in combination with P16-213 (500 to 750 mg/m2), cyclophosphamide (4,000 mg/ m2) and cisplatin (100 mg/m2)' or VPI6-213 (1,000 mg/rn2) and methotrexate
(1,500 mg/m2). In five cases high-dose busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) were given as previously described.2'
In 37 cases high-dose aziridinylbenzoquinone (AZQ; 50 to 1 25 rng/m2 as a single dose given intravenously over a period of 24 hours) was given. AZQ was being given as a phase I study, with the entry dose being twice the conventional solid tumor dose for this drug.25
Committed stem cell assays. CFU-GM and burst-forming unit-erythroid (BFU-E) assays were done precryopreservation and postcryopreservation as previously described with minor modifica-tions29' #{176} to assess the efficacy of the freezing technique.
For the CFU-GM assays, 1 x 10 unfractionated BM cells were cloned in McCoy's media in 1% methylcellulose by using a feeder layer of I x 106 normal human peripheral blood leukocytes immobilized in 0.5% agar as the source of colony-stimulating activity.
The plates were incubated in a 6% CO2 atmosphere at 37#{176}C. Quadruplicate assays were performed on each specimen, and the plates were counted by using an inverted microscope (Leitz, Rockleigh, NJ). An aggregate of 40 or more cells after ten days in culture was considered to be a colony.
For the BFU-E assays, 1 x 10 unfractionated BM cells were cloned in Iscove's media in 1% methylcellulose by using 2 units of sheep Step III erythropoietin (Connaught Laboratories, Swiftwater, PA) per plate. Ten percent phytohemagglutinin-conditioned media was used as the source of burst-promoting factor. The plates were incubated in a 5% CO2 atmosphere at 37#{176}C. A single aggregate or multiple aggregates consisting of 200 or more red cells after 14 days in culture were considered to be a burst. The percent postthaw nucleated cell, CFU-GM, and BFU-E recoveries were calculated as percentages of the total number of these cells frozen.
RESULTS

The nucleated
BM and stem cell recovery data for the 72 transplants are presented in For personal use only. on October 22, 2017. by guest www.bloodjournal.org From
